Cannabidiol (CBD)
PID-18725
Phase 3 small_molecule active
Quick answer
Cannabidiol (CBD) for Clinical High Risk for Psychosis (CHR) is a Phase 3 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- Clinical High Risk for Psychosis (CHR)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active